Financial Support or conflicts of interest: None.
Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by 1H-magnetic resonance spectroscopy in a rat model
Version of Record online: 22 MAR 2010
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 26, Issue 2, pages 356–363, February 2011
How to Cite
Marsman, H. A., Heger, M., Kloek, J. J., Nienhuis, S. L., van Werven, J. R., Nederveen, A. J., ten Kate, F. J., Stoker, J. and van Gulik, T. M. (2011), Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by 1H-magnetic resonance spectroscopy in a rat model. Journal of Gastroenterology and Hepatology, 26: 356–363. doi: 10.1111/j.1440-1746.2010.06326.x
- Issue online: 22 MAR 2010
- Version of Record online: 22 MAR 2010
- Accepted manuscript online: 4 AUG 2010 12:12PM EST
- Accepted for publication 10 March 2010.
- fatty liver;
- liver transplantation;
Background and Aim: Living donors with marked (> 33%) macrovesicular steatosis (MaS) are excluded from living donor liver transplantation procedures. Experimental studies have shown that the development of steatosis can be prevented by supplementation with omega-3 fatty acids (FA), but no studies have investigated the reduction of steatosis using omega-3 FA. The aim of the present study was to investigate whether administration of omega-3 FA is effective in reducing steatosis.
Methods: After fatty liver (FL) induction by a 3-week methionine/choline-deficient (MCD) diet, male Wistar rats were daily administered per gavage omega-3 FA (FL+Omega-3), omega-3-poor lipid solution (FL+Lipid), or NaCl (FL+NaCl) during 2 weeks. Control animals received standard chow without treatment. Determination of steatosis degree was performed before, during, and after treatment by clinical 3.0T 1H-magnetic resonance spectroscopy (1H-MRS) and by histology and gas chromatography at the end of the 2-week treatment period.
Results: Hepatic fat content (1H-MRS) was significantly reduced after 1 and 2 weeks of omega-3 FA treatment. Histological analysis revealed a mild (5–33%) MaS degree in omega-3-treated animals vs severe (> 66%) MaS in the FL+Lipid and FL+NaCl groups. Hepatic omega-6 : 3 FA ratio and total FA content were reduced in the FL+Omega-3 group. Furthermore, de novo lipogenesis (C16, C16 : 1ω7, C18 : 1ω9) was also lowered. The reduction in hepatic fat content was associated with decreased lobular inflammation and hepatic tumor necrosis factor- α and interleukin levels as well as an increased antioxidative capacity.
Conclusion: Omega-3 FA are capable of reversing severe hepatic MaS and ameliorating pathophysiological features of non-alcoholic steatohepatitis such as hepatocellular damage, lobular inflammation, and a reduced antioxidative capacity.